Oxford-Harrington Rare Disease Centre Appoints Influential UK Leader in Health Innovation Policy, Baroness Nicola Blackwood, to its Advisory Council
September 11, 2024 04:00 ET
|
Oxford-Harrington Rare Disease Centre
OXFORD, UK and CLEVELAND, Ohio, US, 11th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at...
MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development
September 09, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
September 04, 2024 07:30 ET
|
Biogen Inc.
Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational...
Foundation for Sarcoidosis Research Expands Scientific Advisory Board with 14 New Experts to Enhance Sarcoidosis Research and Patient Care
August 28, 2024 16:48 ET
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research appoints fourteen new members to serve the organization’s Scientific Advisory Board.
North America Rare Disease Therapeutics Market Size, Trends, Competition, Forecasts & Opportunities, 2019-2023 & 2024-2029
August 27, 2024 09:27 ET
|
Research and Markets
Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "North America Rare Disease Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
August 26, 2024 05:00 ET
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
August 12, 2024 11:00 ET
|
Zealand Pharma
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12,...
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
August 09, 2024 05:00 ET
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS
August 08, 2024 05:00 ET
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS